Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SANTA MONICA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Committee of the Company’s Board of Directors has…